Drug Trial Radar · NCT05953831
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 30, 2024
Primary completion
Sep 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Cardior Pharmaceuticals GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess efficacy and safety of CDR132L on reverse remodeling. In this study, patients with HFpEF (EF ≥50%) or HFmrEF (LVEF 45-49%) will be included.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
CDR132LDrug
CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
PlaceboDrug
Placebo to CDR132L
Primary outcomes
What the sponsor says the trial is designed to measure.
- Left ventricular massTime frame: 6 months
- Left atrial maximum volumeTime frame: 6 months
- Total cardiac extracellular volumeTime frame: 6 months
- Left atrial strainTime frame: 6 months
- Maximum left ventricular wall thicknessTime frame: 6 months
- Age-adjusted e' velocityTime frame: 6 months
- Global longitudinal strainTime frame: 6 months
- E/e'Time frame: 6 months
- Concentration of N-terminal pro B-type natriuretic peptideTime frame: 6 months
- Concentration of high-sensitivity cardiac troponin TTime frame: 6 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.